These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. You Z; Liu SP; Du J; Wu YH; Zhang SZ J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659 [TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and genetic study of BRAF Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640 [TBL] [Abstract][Full Text] [Related]
6. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863 [TBL] [Abstract][Full Text] [Related]
7. High frequency of BRAF V600E mutations in ameloblastoma. Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844 [TBL] [Abstract][Full Text] [Related]
8. Progress towards personalized medicine for ameloblastoma. Gomes CC; Diniz MG; Gomez RS J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150 [TBL] [Abstract][Full Text] [Related]
9. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study. Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088 [TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation mediates invasive and growth features in ameloblastoma. Zhang CX; Zhang LZ; Lin H; Man QW; Liu B Oral Dis; 2024 Oct; 30(7):4426-4439. PubMed ID: 38424736 [TBL] [Abstract][Full Text] [Related]
11. BRAFV600E: implications for carcinogenesis and molecular therapy. Cantwell-Dorris ER; O'Leary JJ; Sheils OM Mol Cancer Ther; 2011 Mar; 10(3):385-94. PubMed ID: 21388974 [TBL] [Abstract][Full Text] [Related]
13. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340 [TBL] [Abstract][Full Text] [Related]
14. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
15. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type. Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428 [TBL] [Abstract][Full Text] [Related]
16. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas. Kumamoto H; Takahashi N; Ooya K J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485 [TBL] [Abstract][Full Text] [Related]
17. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588 [TBL] [Abstract][Full Text] [Related]
18. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. Uribe P; Andrade L; Gonzalez S J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232 [TBL] [Abstract][Full Text] [Related]
20. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]